Keiya Uriu

This study determines the structure of the 2026 Bundibugyo virus glycoprotein and identifies conserved epitopes for antibody therapeutics and pan-ebolavirus vaccines.

This study experimentally infects horseshoe bats with SARS-CoV-2, showing low-level persistent viral replication without disease, and identifies host mechanisms that enable viral coexistence.

This study evaluates the neutralizing antibody response induced by XEC-based monovalent vaccines against multiple SARS-CoV-2 variants, showing enhanced immunity against JN.1 subvariants compared to other variants.

This study identifies the non-spike R204P mutation in the SARS-CoV-2 Omicron XEC variant as a driver of increased inflammation and pathogenicity through NF-κB activation.

This study evaluates the humoral immune response induced by LP.8.1-based vaccines against multiple SARS-CoV-2 variants, showing effective cross-neutralization and immune boosting.

This paper introduces CoVFit, a protein language model that predicts SARS-CoV-2 variant fitness using spike protein sequences, identifying fitness-enhancing mutations and predicting emerging variants.

This study compares the antiviral humoral immunity induced by two JN.1 monovalent mRNA vaccines against multiple SARS-CoV-2 Omicron subvariants and XEC, showing both vaccines boost immunity with statistical significance.

This study analyzes the virological characteristics of the SARS-CoV-2 XEC variant, showing it has higher infectivity and immune evasion compared to KP.3.1.1, contributing to its higher reproductive number and potential dominance.

This paper investigates the virological properties of the SARS-CoV-2 KP.3.1.1 variant, finding it has higher transmissibility and immune evasion compared to KP.3.

This study evaluates the virological properties of SARS-CoV-2 variants KP.3, LB.1, and KP.2.3, finding higher reproduction numbers and immune evasion compared to JN.1.

This study investigates the virological properties of the SARS-CoV-2 KP.2 variant, finding it has higher viral fitness and immune resistance compared to JN.1, contributing to its rapid spread.

The paper assesses the humoral immune response to XBB.1.5 vaccine in infection-naive and XBB-infected individuals against various SARS-CoV-2 variants.

This study investigates the virological properties of the SARS-CoV-2 JN.1 variant, focusing on its mutations and potential immune evasion capabilities.